A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy Journal Article
| Authors: | Osborne, J. R.; Green, D. A.; Spratt, D. E.; Lyashchenko, S.; Fareedy, S. B.; Robinson, B. D.; Beattie, B. J.; Jain, M.; Lewis, J. S.; Christos, P.; Larson, S. M.; Bander, N. H.; Scherr, D. S. |
| Article Title: | A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy |
| Abstract: | Purpose In this pilot study we explored the feasibility of 89Zr labeled J591 monoclonal antibody positron emission tomography of localized prostate cancer. Materials and Methods Before scheduled radical prostatectomy 11 patients were injected intravenously with 89Zr-J591, followed 6 days later by whole body positron emission tomography. Patients underwent surgery the day after imaging. Specimens were imaged by ex vivo micro positron emission tomography and a custom 3 Tesla magnetic resonance scanner coil. Positron emission tomography images and histopathology were correlated. Results Median patient age was 61 years (range 47 to 68), median prostate specific antigen was 5.2 ng/ml (range 3.5 to 12.0) and median biopsy Gleason score of the 11 index lesions was 7 (range 7 to 9). On histopathology 22 lesions were identified. Median lesion size was 5.5 mm (range 2 to 21) and median Gleason score after radical prostatectomy was 7 (range 6 to 9). Eight of 11 index lesions (72.7%) were identified by in vivo positron emission tomography. Lesion identification improved with increasing lesion size for in vivo and ex vivo positron emission tomography (each p <0.0001), and increasing Gleason score (p = 0.14 and 0.01, respectively). Standardized uptake values appeared to correlate with increased Gleason score but not significantly (p = 0.19). Conclusions To our knowledge this is the first report of 89Zr-J591/prostate specific membrane antigen positron emission tomography in localized prostate cancer cases. In this setting 89Zr-J591 bound to tumor foci in situ and positron emission tomography identified primarily Gleason score 7 or greater and larger tumors, likely corresponding to clinically significant disease warranting definitive therapy. A future, larger clinical validation trial is planned to better define the usefulness of 89Zr-J591 positron emission tomography for localized prostate cancer. © 2014 by American Urological Association Education and Research, Inc. |
| Keywords: | adult; clinical article; human tissue; aged; middle aged; cancer surgery; histopathology; nuclear magnetic resonance imaging; prospective study; prostate specific antigen; tumor volume; cohort analysis; in vivo study; in vitro study; prostate cancer; gleason score; prostatic neoplasms; monoclonal antibody j591; prostate specific membrane antigen; pilot study; prostatectomy; prostate biopsy; positron-emission tomography; prostate hypertrophy; ex vivo study; zirconium; glutamate carboxypeptidase ii; whole body pet; human; male; priority journal; article; j591 monoclonal antibody |
| Journal Title: | Journal of Urology |
| Volume: | 191 |
| Issue: | 5 |
| ISSN: | 0022-5347 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2014-05-01 |
| Start Page: | 1439 |
| End Page: | 1445 |
| Language: | English |
| DOI: | 10.1016/j.juro.2013.10.041 |
| PROVIDER: | scopus |
| PUBMED: | 24135437 |
| PMCID: | PMC4411555 |
| DOI/URL: | |
| Notes: | J. Urol. -- Export Date: 2 June 2014 -- CODEN: JOURA -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work